The use of small molecule Nrf2 activators may offer additional approaches either as preventive agents or in combination therapies with other treatment options to address the detrimental effects of Aβ on mitochondrial and synaptic function as well as the metabolic/bioenergetic abnormalities encompassing the complex and multifactorial pathways leading to AD pathogenesis. Here, NFE2L2 is linked to Alzheimer disease.